| Name | Title | Contact Details |
|---|
Mumbais #1 Generic Medicine Pharmacy 100+ Stores | 200 Crore+ Savings Delivered | Trusted by over 15 Lakhs+ Customer
The home infusion industry turns to KORU Medical Systems to help patients and medical professionals improve infusion therapy experiences and we have a passion and vision for doing just that! We focus on home and specialty infusion solutions, emphasizing responsive problem-solving for our customers with careful consideration to the patient experience. The company was incorporated in March 1980 and is now publicly traded on the NASDAQ Capital Market (NASDAQ: KRMD). We are located in Chester, NY (USA), just 60 miles northwest of New York City. Our primary products include the FREEDOM60® and FreedomEdge® Syringe Infusion Systems, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets.
A new, innovative product that allows a single caregiver to reposition a patient up in bed in less than ten seconds with the simple push of a button. Learn more here.
Aphena Pharma Solutions New Jersey is a Whippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.